Long-acting growth hormone-releasing hormone analogue

CJC-1295

aka CJC-1295 DAC · DAC:GRF

Evidence grade
Grade C: Preliminary human data
for raising growth hormone for body composition, recovery and sleep
User score everyone · n = 12
US FDA Not approved checked 2026-11-13
WADA 2026 Prohibited (S2.2.4) at all times · checked 2026-11-13
EU FDA's 2024 review found no EMA-authorized CJC-1295 product; a later authorization was not found. · checked 2026-11-13

Goals: Sleep · Recovery & injury · Fat loss · Muscle & strength Compare with another peptide →

User reports

approximate — combined from two independent Reddit reads

Men 45–60

1 man aged 45–60

small sample · n = 1

Outcome positive 1 of 1

Benefits other 1 of 1

Side effects none reported

Stopped 0 of 1 Used with other compounds 1 of 1

All men

2 men

small sample · n = 2

Outcome positive 2 of 2 · mixed 1 of 2

Benefits endurance 1 of 2 · other 1 of 2 · sleep 1 of 2

Side effects flushing 1 of 2

Stopped 0 of 2 Used with other compounds 2 of 2

Everyone

12 people

  • Positive: 6 of 12 (50%)
  • Mixed: 1 of 12 (8%)
  • Negative: 2 of 12 (17%)
  • Unclear: 3 of 12 (25%)
Benefits reported of 12
Benefits reported (n = 12)
ItemReports
Fat loss3 of 12 (25%)
Muscle3 of 12 (25%)
Sleep3 of 12 (25%)
Other2 of 12 (17%)
Recovery2 of 12 (17%)
Endurance1 of 12 (8%)
Energy1 of 12 (8%)
Skin1 of 12 (8%)
Side effects reported of 12
Side effects reported (n = 12)
ItemReports
Heart rate up2 of 12 (17%)
Other2 of 12 (17%)
Flushing1 of 12 (8%)
Injection site1 of 12 (8%)
Insomnia1 of 12 (8%)
More hunger1 of 12 (8%)
Vivid dreams1 of 12 (8%)
Water retention1 of 12 (8%)
Why people stopped of 12
Why people stopped (n = 12)
ItemReports
Side effects1 of 12 (8%)

Stopped 1 of 12 (8%) Used with other compounds 12 of 12 (100%)

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.

In their words

  • “After the second day- I noticed an increase in endurance at the gym”

  • “When I was just on cjc-1295 I was getting shredded pretty fast.”

  • “Rapid heart beat like never before, extreme dizziness, and completely blurry vision to where I could hardly see.”

  • “This morning I threw the vial away and decided I’m done with that compound.”

  • “I like CJC-1295 no dac with Ipa personally.”

  • “About 4 weeks in, I noticed a weird "pop" in my training. Weights that used to be my heavy sets started feeling like RPE 7.”

  • “Rapid heart beat, dizziness, and swollen throat.”

  • “At night it makes me feel racy, and sweaty. So hard to sleep on it”

Read summaries and method notes

Read 1. No man aged 45–60 was identifiable; the only explicitly age/sex-qualified male in the counted sample was a 36-year-old using a CJC/ipamorelin blend with BPC-157. He reported better sleep and endurance but also flushing, so his result is mixed. Other users reported fat loss on CJC alone, sleep/recovery/energy while stacking CJC with HGH, and a severe recurrence-cycle reaction on CJC/ipamorelin involving rapid heartbeat, dizziness, blurred vision and syncope that led the user to discard the vial. Water retention and hunger were specifically associated by one reporter with adding ipamorelin, illustrating why CJC-alone and CJC/ipa experiences should not be treated as equivalent. Most reports were stacked, substantially weakening attribution.

Read 2. One man aged 45–60 (46M, positive, CJC no-DAC with ipamorelin). Eleven users from 16 threads: 5 positive, 1 mixed, 2 negative, 3 unclear — muscle, fat loss, strength jumps after week 4, recovery, deep sleep. Major cautions: raised heart rate, a severe systemic allergic reaction (dizziness, swollen throat), a delayed histamine/injection-site reaction that forced a stop, vivid dreams, night sweats and insomnia. All 11 stacked it, so there is no standalone CJC-1295 data.

Note 1. CJC-1295 was usually combined with ipamorelin, HGH or BPC-157. DAC/no-DAC distinctions were often omitted by users, so they were not inferred.

Note 2. 100% stacked (ipamorelin, BPC-157 or AOD-9604). Histamine reactions, flushing and night-time tachycardia/insomnia recur.

Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.

Summary

Synthetic growth hormone-releasing hormone analogue with an albumin-binding drug affinity complex (DAC). Short studies show sustained GH/IGF-1 rises and persistent pulses, but also elevated trough GH; unchanged natural physiology and physique/sleep benefits are not established. Clinical benefit from combining it with Ipamorelin was not found. Results for DAC cannot simply be transferred to “no DAC” preparations.

Proposed mechanism

  • CJC-1295 with DAC: half-life extends via albumin binding → GH elevation 2–10× for ≥6 days
  • Stimulates pituitary GHRH receptors → sustained GH release
  • GH pulses persisted in a short study, while trough GH rose; unchanged natural physiology is not established.
  • Increases IGF-1 levels significantly

Safety

  • Injection-site reactions, headache, gastrointestinal symptoms and flushing were frequent in small studies
  • FDA reports increased heart rate and systemic vasodilatory reactions
  • A participant died in an unpublished discontinued trial; causality is unestablished
  • Long-term safety and compounded-product quality are uncertain

From labels, regulators and trials. No signal in small studies ≠ safe.

Evidence C raising growth hormone for body composition, recovery and sleep

C stands. Two small randomized pharmacology studies and one uncontrolled study show GH and IGF-1 rise; none measured body composition, recovery or sleep, and the only disease trial was halted and never published.

Human trials · 2

  1. PMID 163526832006Two randomized, double-blind, placebo-controlled ascending-dose studies 66 people

    Healthy adults aged 21–61 years

    Subcutaneous DAC analogue raised GH and IGF-1 for days; clinical body-composition outcomes were not established. Source

  2. PMID 170186542006Uncontrolled before-and-after pharmacology study 12 people

    Healthy adult men

    GH pulsatility persisted one week after a single injection, while trough GH and IGF-1 increased. Source

Bar length = trial size on a log scale.

Dose ranges

Reported ranges from labels and studies, with context. Not a recommendation.

  • clinical trial
    DAC form: single subcutaneous doses of 30–250 micrograms/kg; a separate multiple-dose study used 20–60 micrograms/kg weekly or every two weeks Source

Editorial ratings EDITORIAL

Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.

  • Safety withdrawn — see safety update —
  • Sleep 4.5 out of 5
  • Recovery 4 out of 5
  • Cognitive 3.5 out of 5

Sources

  1. pubmed.ncbi.nlm.nih.gov/16352683/
  2. pubmed.ncbi.nlm.nih.gov/17018654/
  3. fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-pres
  4. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  5. fda.gov/media/183819/download
  6. fda.gov/media/183891/download
  7. fda.gov/media/185642/download
  8. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c

Reddit threads read · 10

Research checked 2026-11-13.